Skip to content

A Study Comparing Two Ayurvedic Treatments (Aargavadhadi Kashaya and Bhrungyadi Kashaya) After Bloodletting Therapy in Patients with Urticaria (Kotha)

A Comaparative Clinical study to evaluate the efficacy of Aargavadhadi kashaya and Bhrungyaadi kashaya after raktamokshan in Kotha with special reference to urticaria - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112847
Enrollment
84
Registered
2026-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L50- Urticaria

Interventions

None listed

Sponsors

R.A. Podar Medical College ,Worli, Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patient presenting with sign and symptoms mentioned by Ayurveda Text like:- A)raag( redness) B)Daha(Burning sensation) C)Kandu(itching) D)toda(Prickling sensation) E)Varati danshavat shotha(wheals/hives) 2)Patient having acute & chronic Urticaria 3) Patients of age group between 16-70yrs. 4)Patient not dependent on other treatment for hives ,itching, redness in Kandu

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
to evaluate the efficacy of aargavadhadi kashaya and bhrungyaadi kashaya after raktamokshan in kotha in terms of clinical improvement in signs and symptoms of kothaTimepoint: to evaluate the efficacy of aargavadhadi kashaya and bhrungyaadi kashaya after raktamokshan in kotha in terms of clinical improvement in signs and symptoms of kotha

Secondary

MeasureTime frame
reduction in grades of symptoms and clinically improvement in sign and symptoms of kothaTimepoint: total 8 weeks 7,14,21,28,42,57 th days

Countries

India

Contacts

Public ContactDr Meenakshi Subhash Rewdkar Kole
drmrevadkar@yahoo.com9757476325

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026